JPH03178916A - Skin external agent - Google Patents
Skin external agentInfo
- Publication number
- JPH03178916A JPH03178916A JP31675389A JP31675389A JPH03178916A JP H03178916 A JPH03178916 A JP H03178916A JP 31675389 A JP31675389 A JP 31675389A JP 31675389 A JP31675389 A JP 31675389A JP H03178916 A JPH03178916 A JP H03178916A
- Authority
- JP
- Japan
- Prior art keywords
- active ingredient
- compound
- formula
- sebum
- tannin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 25
- 229920001864 tannin Polymers 0.000 claims abstract description 21
- 235000018553 tannin Nutrition 0.000 claims abstract description 21
- 239000001648 tannin Substances 0.000 claims abstract description 21
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Chinese gallotannin Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 14
- 229920002824 gallotannin Polymers 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims 4
- 210000002374 sebum Anatomy 0.000 abstract description 23
- 239000000203 mixture Substances 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 10
- 238000003786 synthesis reaction Methods 0.000 abstract description 10
- 239000002674 ointment Substances 0.000 abstract description 5
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 abstract description 4
- 239000006071 cream Substances 0.000 abstract description 4
- 230000028327 secretion Effects 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 239000011782 vitamin Substances 0.000 abstract description 3
- 235000013343 vitamin Nutrition 0.000 abstract description 3
- 229940088594 vitamin Drugs 0.000 abstract description 3
- 229930003231 vitamin Natural products 0.000 abstract description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract description 2
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 abstract description 2
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 abstract description 2
- 230000007794 irritation Effects 0.000 abstract description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 abstract description 2
- 239000011593 sulfur Substances 0.000 abstract description 2
- 229910052717 sulfur Inorganic materials 0.000 abstract description 2
- 239000004094 surface-active agent Substances 0.000 abstract description 2
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 abstract description 2
- 229960001325 triclocarban Drugs 0.000 abstract description 2
- 229960003500 triclosan Drugs 0.000 abstract description 2
- 150000003722 vitamin derivatives Chemical class 0.000 abstract description 2
- 229930007845 β-thujaplicin Natural products 0.000 abstract description 2
- 241000365112 Monsonia angustifolia Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 240000005001 Paeonia suffruticosa Species 0.000 abstract 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 abstract 1
- 229940121375 antifungal agent Drugs 0.000 abstract 1
- 239000003429 antifungal agent Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 10
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 8
- 239000003205 fragrance Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 229940074391 gallic acid Drugs 0.000 description 5
- 235000004515 gallic acid Nutrition 0.000 description 5
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 229940032094 squalane Drugs 0.000 description 5
- QJYNZEYHSMRWBK-NIKIMHBISA-N 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose Chemical compound OC1=C(O)C(O)=CC(C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 QJYNZEYHSMRWBK-NIKIMHBISA-N 0.000 description 4
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 229960000458 allantoin Drugs 0.000 description 4
- -1 helocarban Chemical compound 0.000 description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- GDVRUDXLQBVIKP-HQHREHCSSA-N 1-O-galloyl-beta-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(=O)C1=CC(O)=C(O)C(O)=C1 GDVRUDXLQBVIKP-HQHREHCSSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 229920000296 Glucogallin Polymers 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 229940099259 vaseline Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical group OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- 235000014692 zinc oxide Nutrition 0.000 description 2
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- WMBWREPUVVBILR-GHTZIAJQSA-N (+)-gallocatechin gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-GHTZIAJQSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- OEOIWYCWCDBOPA-UHFFFAOYSA-N 6-methyl-heptanoic acid Chemical compound CC(C)CCCCC(O)=O OEOIWYCWCDBOPA-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 235000005491 Geranium thunbergii Nutrition 0.000 description 1
- 244000105059 Geranium thunbergii Species 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- ACEWLPOYLGNNHV-UHFFFAOYSA-N Ibuprofen piconol Chemical compound C1=CC(CC(C)C)=CC=C1C(C)C(=O)OCC1=CC=CC=N1 ACEWLPOYLGNNHV-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- JDLSRXWHEBFHNC-UHFFFAOYSA-N Ufenamate Chemical compound CCCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 JDLSRXWHEBFHNC-UHFFFAOYSA-N 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- RJINLRBSXMOGAQ-KMNHUKDVSA-N [(2r,3r,4s,5r)-6-hydroxy-3,4,5-tris[(3,4,5-trihydroxybenzoyl)oxy]oxan-2-yl]methyl 3,4,5-trihydroxybenzoate Chemical compound C([C@H]1OC([C@@H]([C@@H](OC(=O)C=2C=C(O)C(O)=C(O)C=2)[C@@H]1OC(=O)C=1C=C(O)C(O)=C(O)C=1)OC(=O)C=1C=C(O)C(O)=C(O)C=1)O)OC(=O)C1=CC(O)=C(O)C(O)=C1 RJINLRBSXMOGAQ-KMNHUKDVSA-N 0.000 description 1
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- MXOAEAUPQDYUQM-UHFFFAOYSA-N chlorphenesin Chemical compound OCC(O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-UHFFFAOYSA-N 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 description 1
- GJMUCSXZXBCQRZ-UHFFFAOYSA-N geraniin Natural products Oc1cc(cc(O)c1O)C(=O)OC2OC3COC(=O)c4cc(O)c(O)c(O)c4c5cc(C(=O)C67OC3C(O6)C2OC(=O)c8cc(O)c(O)c9OC%10(O)C(C(=CC(=O)C%10(O)O)C7=O)c89)c(O)c(O)c5O GJMUCSXZXBCQRZ-UHFFFAOYSA-N 0.000 description 1
- 229930194078 geranin Natural products 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229950005954 ibuprofen piconol Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000008164 mustard oil Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 229950010121 ufenamate Drugs 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野]
本発明は皮膚外用剤に関する。更に詳しくは、タンニン
化合物を有効成分とし、皮脂の分泌過剰によっておこる
皮膚炎等の脂漏性疾患に優れた効果を有する皮膚外用剤
に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to an external preparation for skin. More specifically, the present invention relates to an external skin preparation containing a tannin compound as an active ingredient and having excellent effects on seborrheic diseases such as dermatitis caused by excessive secretion of sebum.
[従来の技術]
タンニンは古くから漢方薬として利用されている種々の
生薬成分としてよく知られており、日本薬局方にはタン
ニン酸として収載されている。薬効としては収斂作用、
抗酸化作用などが報告されている。またガロタンニンは
グルコースと没食子酸から構成されており、通常没食子
酸の結合位置の異なる種々の化合物の混合物である。[Prior Art] Tannin is well known as a component of various crude drugs that have been used as Chinese herbal medicine since ancient times, and is listed as tannic acid in the Japanese Pharmacopoeia. Medicinal effects include astringent action,
Antioxidant effects have been reported. Further, gallotannin is composed of glucose and gallic acid, and is usually a mixture of various compounds in which the gallic acid is bound at different positions.
一方、今日まで特異的に皮脂分泌抑制を示し、それら以
外の器官に影響しないような化合物は知られていない。On the other hand, to date, no compound has been known that specifically inhibits sebum secretion and does not affect other organs.
経口投与用に皮脂抑制剤シブロチロンアセデートがある
が、経口投与は局所使用よりも副作用が大きいことが多
い。また、その抗アンドロゲン性のために、シブロチロ
ンアセテートは女性にのみしか用いることができない。The sebum suppressant sibrothyrone acedate is available for oral administration, but oral administration often has greater side effects than topical use. Also, due to its anti-androgenic properties, sibrothyrone acetate can only be used by women.
F発明が解決しようとする課題]
本発明者らは、特異的に皮脂分泌抑制を示し、それら以
外の器官に影響しないような化合物を得るべく鋭意研究
したところ、タンニン化合物を有効成分として配合して
なる外用剤が、この目的を達成できることを見いだし、
本発明を完成するに至った。Problems to be Solved by Invention F] The present inventors conducted intensive research to obtain a compound that specifically inhibits sebum secretion and does not affect other organs, and found that a tannin compound was blended as an active ingredient. discovered that a topical preparation consisting of
The present invention has now been completed.
[課題を解決するための手段]
すなわち本発明は、タンニン化合物を有効成分として含
有することを特徴とする皮膚外用剤である。[Means for Solving the Problems] That is, the present invention is an external skin preparation characterized by containing a tannin compound as an active ingredient.
以Vζ、本発明の構成について詳述する。Hereinafter, the configuration of the present invention will be explained in detail.
本発明に係わるタンニン化合物とは、通常、没食子酸と
フェノールカルボン酸等の水酸基がエステル結合したも
のを言い、例えば、没食子酸がカテコールとエステル結
合したガロカテキン、エビカチキン、ガロカテキンガレ
ート等の縮合型タンニン、没食子酸がグルコースとエス
テル結合したガロタンニン(=ガロイルグルコース)等
の加水分解型タンニンなどをあげることができる。The tannin compound according to the present invention usually refers to a compound in which a hydroxyl group such as gallic acid and a phenolic carboxylic acid is bonded to an ester. For example, a tannin compound in which gallic acid is bonded to a catechol by an ester bond such as gallocatechin, evika chicken, gallocatechin gallate, etc. Examples include hydrolyzed tannins such as gallotannin (= galloylglucose), in which gallic acid is ester-bonded with glucose.
本発明に使用するタンニン化合物りよ上記のものであれ
ば、いずれでもよいが下記一般式で表される
テトラ−GG ペンタ−GG ヘキサ−GGウン
テ゛カーGG
本発明に用いられるタンニン化合物は、通例、
勺薬、五倍子、牡丹皮、ゲンノショウコ等から抽出した
ものを用いるほか、化学的合成によっても製造される。The tannin compound used in the present invention may be any of the above compounds, but is represented by the following general formula: tetra-GG penta-GG hexa-GG counter GG In addition to using extracts from plants such as Gobaiko, Botanpi, Gennoshoko, etc., it is also produced by chemical synthesis.
例えばり薬からガロタンニンを得る場合には、勺薬を5
0%アセトン溶液で抽出後、得られた抽出破に飽和食塩
水および酢酸エチルを加える。酢酸エチル移行部の溶媒
を留去し、ガロタンニンを得る。必要に応じて高速液体
クロマトグラフィー等で分離精製する。For example, if you want to obtain gallotannin from a medicine, add 5
After extraction with 0% acetone solution, saturated saline and ethyl acetate are added to the resulting extracted solution. The solvent in the ethyl acetate transfer zone is distilled off to obtain gallotannin. Separate and purify using high performance liquid chromatography, etc., if necessary.
本発明の皮膚外用剤において配合するタンニン化合物の
量は特に限定はしないが、全組成中0.0001〜5重
量%、好ましくは0.001,2重量%が望ましい。0
.0001重景%未満でむよ、本発明の十分な皮脂抑制
効果か得られず、5重量%を超えると着色し、製剤上好
ましくない。The amount of the tannin compound incorporated in the skin external preparation of the present invention is not particularly limited, but it is preferably 0.0001 to 5% by weight, preferably 0.001.2% by weight based on the total composition. 0
.. If it is less than 0,001% by weight, the sufficient sebum-suppressing effect of the present invention cannot be obtained, and if it exceeds 5% by weight, it will be colored, which is not preferable in terms of formulation.
本発明の皮膚外用剤には、タンニン化合物のほかにイオ
ウ、ヒノキチオール、トリクロサン、トリクロロカルバ
ニリド、クロルヘキシジン塩酸塩、クロルヘキシジング
ルコン酸塩、へロカルバン、クロロフエネシン、塩化ベ
ンゼトニウム、塩化ベンザルコニウム、塩化リゾデーム
、塩酸アルキルジアミノエチルグリジン、イソプロピル
メチルフェノール、安息香酸、感光素201号、チモー
ル、ヘキサクロロフエン、ベルベリン、デオキソロンな
どの抗菌剤、またビタミ′)A、B2、B6、B12、
C1DXE1ビオチン、ニコチン酸等のビタミン剤やザ
リヂル酸、レゾルシン等の角質剥離剤、グリチルレチン
酸、グリチルリチン酸、アラントイン、イプシロンアミ
ノカプロン酸、フルフェナム酸ブチル、アズレン、カン
ファー、塩化亜鉛、亜鉛華、メント−ル、インドメタシ
ン、イブプロフェンピコノール、メフェナム酸ならびに
それらの誘導体等の抗炎症剤、エヂニルエストラジオー
ルのような皮脂抑制剤、さらに亜鉛およびその化合物、
乳酸および性状によっても異なるが、油分、界面活性剤
、水、エタノール、保湿剤、増粘剤、香料、色素等を本
発明の効果を損なわない範囲で適宜配合することができ
る。In addition to tannin compounds, the skin external preparation of the present invention includes sulfur, hinokitiol, triclosan, trichlorocarbanilide, chlorhexidine hydrochloride, chlorhexidine gluconate, helocarban, chlorophenesin, benzethonium chloride, benzalkonium chloride, Antibacterial agents such as lysodem, alkyldiaminoethylglydine hydrochloride, isopropylmethylphenol, benzoic acid, photosensor No. 201, thymol, hexachlorophene, berberine, deoxolone, and vitamins A, B2, B6, B12,
C1DXE1 Vitamins such as biotin and nicotinic acid, exfoliating agents such as zarydylic acid and resorcinol, glycyrrhetinic acid, glycyrrhizic acid, allantoin, epsilon aminocaproic acid, butyl flufenamate, azulene, camphor, zinc chloride, zinc white, menthol, Anti-inflammatory agents such as indomethacin, ibuprofen piconol, mefenamic acid and their derivatives, sebum suppressants such as edinyl estradiol, as well as zinc and its compounds,
Although it varies depending on the lactic acid and its properties, oils, surfactants, water, ethanol, humectants, thickeners, fragrances, pigments, and the like can be appropriately blended within the range that does not impair the effects of the present invention.
本発明の皮膚外用剤の性状は、クリーム、軟膏、ローシ
ョン等、外皮に適用できる性状のものであればいずれで
も良い。The skin external preparation of the present invention may be in any form as long as it can be applied to the skin, such as a cream, ointment, or lotion.
し発明の効果]
本発明の皮膚外用剤は非常に良好な可逆的、局所的皮脂
抑制効果を示す。また本発明に係わるタンニン化合物は
非常に良く皮膚に浸透し、はとんど刺激を与えないので
、特に脂漏性疾患の治療に適する。この活性は特異的に
皮脂に向けられ、それら以外の器官に全く影響しない。[Effects of the Invention] The skin external preparation of the present invention exhibits a very good reversible and local sebum suppressing effect. Furthermore, the tannin compounds according to the present invention penetrate the skin very well and cause little irritation, so they are particularly suitable for the treatment of seborrheic diseases. This activity is specifically directed towards sebum and has no effect on other organs.
[実施例]
次に実施例をあげて、本発明をにさらに具体的に説明す
る。本発明番よこれにより限定されるものではない。[Example] Next, the present invention will be described in more detail with reference to Examples. The present invention is not limited thereto.
[皮脂合成抑制率試験]
一群5匹の雌ハムスターにテストステロン0.5μg/
20m1アセトン/1日を塗布し耳脂腺における皮脂合
成を刺激し、24時間経過後、本発明のタンニン化合物
100μg/アセトン/1日を塗布し、その皮脂合成抑
制率を測定した。尚、テストステロンを塗布したt=け
てタンニン化合物を塗布しないものを対照群とした。[Sebum synthesis inhibition rate test] Testosterone 0.5μg/group to 5 female hamsters
20 ml of acetone/day was applied to stimulate sebum synthesis in the ear sebaceous glands, and after 24 hours, 100 μg/acetone/day of the tannin compound of the present invention was applied, and the inhibition rate of sebum synthesis was measured. In addition, a control group was defined as t=1 to which testosterone was applied and a control group to which no tannin compound was applied.
皮脂合成の程度は放射性アセテートによる耳バイオプシ
イーの培養により測定される[(Hall D。The degree of sebum synthesis is determined by incubation of ear biopsies with radioactive acetate [(Hall D.
W、R,)他、ハムスターの耳脂腺脂質形成のホルモン
制御、Arch、Dermatol、 Res、、27
5.1(1,983)]。その試験は脂質中へ付加した
放射性アセテートの転化を基にし、ヘキサンで抽出した
後シンデレージョンカウンターで測定した。その結果を
表−1に示した。百分率は100%を越えることができ
る。W, R, et al., Hormonal control of otic sebaceous gland lipid formation in hamsters, Arch, Dermatol, Res, 27
5.1 (1,983)]. The test was based on the conversion of radioactive acetate added into the lipids, which was measured in a cindersion counter after extraction with hexane. The results are shown in Table-1. The percentage can exceed 100%.
すなわち非常に強い活性の化合物はテストステロンによ
り刺激された活性および脂腺の基底皮脂合成をともに抑
制する。Thus, highly active compounds suppress both the testosterone-stimulated activity and the basal sebum synthesis of the sebaceous glands.
皮脂合成抑制率
(%)
の計算式は
表
表−1かられかるように本発明のタンニン化合物は、優
れた皮脂合成抑制能を有している。更にガロイルグルコ
ースはその中でも、特に優れた皮脂合成抑制能を有して
いる。As shown in Table 1, the formula for calculating the sebum synthesis inhibition rate (%) shows that the tannin compound of the present invention has an excellent ability to inhibit sebum synthesis. Furthermore, among them, galloylglucose has a particularly excellent ability to inhibit sebum synthesis.
実施例1 重量%1)固
体パラフィン 10.02)ピー
スワックス 10.03)スクワ
ラン 10.04)ペンタガ
ロイルグルコース 1.05)香料
適量6)ワセリン
69.0」二記成分を混合し、
混合物を80℃に加熱溶解した後、攪拌冷却を行い、軟
膏を得た。Example 1 Weight % 1) Solid paraffin 10.02) Peace wax 10.03) Squalane 10.04) Pentagalloylglucose 1.05) Fragrance
Appropriate amount 6) Vaseline
69.0" Mix the two components,
After heating and dissolving the mixture at 80° C., the mixture was stirred and cooled to obtain an ointment.
[皮脂抑制効果試験]
上記処方、製造法で得た軟膏タイプの皮膚外用剤を使用
した。[Sebum Suppression Effect Test] An ointment-type skin external preparation obtained by the above-mentioned formulation and manufacturing method was used.
(使用対象および観察期間)
15〜28歳までの脂漏性皮膚炎の患者20名に2週間
使用させた。(Targets for use and observation period) Twenty patients with seborrheic dermatitis aged 15 to 28 years were used for two weeks.
(使用方法)
化粧石鹸を用いて顔面をよく洗浄した後、皮脂の上にの
み、前記した軟膏タイプの皮膚外用剤を1日に1〜3回
塗布せしめた。(How to use) After thoroughly washing the face with cosmetic soap, the above-mentioned ointment-type skin preparation for external use was applied only on the sebum 1 to 3 times a day.
(皮脂の81J定)
使用前と2週間使用後の総皮脂量をガラスカップ法で皮
脂を採取して重量法[Ohokawa、H,、et a
l、、Anal、Biochem、、95.35135
8(1979)]にて測定した。皮脂量は以下の式のご
とく相対比で表した。(81J of sebum) The total amount of sebum before use and after 2 weeks of use was collected using the glass cup method and weighed using the gravimetric method [Ohokawa, H., et al.
l,,Anal,Biochem,,95.35135
8 (1979)]. The amount of sebum was expressed as a relative ratio as shown in the following formula.
減少率エ − ′−の ×100使用前
の総皮脂量
(全般改善度)
使用前に比較して外用剤塗布による症状の改善度を軽快
(廿)、やや軽快(+)、不変(±)、増悪(−)の4
段階に分けた。Reduction rate E - '-'s ×100 Total sebum volume before use (general improvement level) Compared to before use, the degree of improvement in symptoms due to topical agent application was reduced (廿), somewhat reduced (+), and unchanged (±) , exacerbation (-) of 4
Divided into stages.
2
8
男
0
廿
2
男
1
廿
4
男
十
5
男
+
8
男
±
5
男
2
廿
8
男
+
1
女
+
2
女
±
0
7
女
2
+
1
3
女
±
2
2
女
+
男10名、女10名計20名の臨床テスト結果、平均皮
脂減少率は8.9%であり、また外用剤塗布による症状
の改善度は軽快(25%)、やや軽快(40″X)、不
変(35%)、増悪(0%)であり、本発明の皮膚外用
剤剤の効果が立証された。2 8 Male 0 廿2 Male 1 廿4 Male 15 Male + 8 Male ± 5 Male 2 廿8 Male + 1 Female + 2 Female ± 0 7 Female 2 + 1 3 Female ± 2 2 Female + 10 males, 10 females The results of clinical tests on 20 famous people showed that the average sebum reduction rate was 8.9%, and the degree of improvement of symptoms by applying topical preparations was mild (25%), mild (40″X), and unchanged (35%). , exacerbation (0%), demonstrating the effectiveness of the skin external preparation of the present invention.
実施例2 化粧水
1)グリセリン
2)クエン酸
3)クエン酸ソーダ
4)アラントイン
重量%
5.0
0.03
0.05
0.1
4
5)エタノール(95%) ]、
0.06)ポリオキシエチレン(以下、POEという)
(15モル)オレイルアルコールエーテル
1.07)ベンタガ1コイルグルコー
ス 1゜08)紫外線吸収剤
0.19)香料
0.110)防腐剤
0.111)色素
適量12)精製水 残余5
)6)9) 10)を室温にて混合溶解し、同じく室温
にて混合溶解した1)2)3)4)?)8) 11)1
2)中へ撹拌添加して化粧水を得た。Example 2 Lotion 1) Glycerin 2) Citric acid 3) Sodium citrate 4) Allantoin Weight % 5.0 0.03 0.05 0.1 4 5) Ethanol (95%) ],
0.06) Polyoxyethylene (hereinafter referred to as POE)
(15 mol) oleyl alcohol ether
1.07) Bentaga 1 Coil Glucose 1゜08) Ultraviolet absorber
0.19) Fragrance
0.110) Preservatives
0.111) Pigment
Appropriate amount 12) Purified water Remainder 5
) 6) 9) 10) were mixed and dissolved at room temperature, and 1) 2) 3) 4)? )8) 11)1
2) A lotion was obtained by stirring and adding to the solution.
実施例3 化粧水
1)ソルビト−ル(70%)
2)グリセリン
3)水
4)グリチルリチン酸
5)ビタミンB2
6)ボタンピ抽出タンニン
重量%
3.0
5.0
70.899
0.5
0.07
0、O3
5
7) P OE硬化ヒマシ油誘導体 0.5
8)エタノール 20.09
)エチニルエストラジオール 0.00110
)香料 適量1、)2
)3)4.)の成分を混合溶解し、これに、5)6)?
)8)9) 10)の混合溶液を攪拌しながら加えて均
一な溶液として化粧水を得た。Example 3 Lotion 1) Sorbitol (70%) 2) Glycerin 3) Water 4) Glycyrrhizic acid 5) Vitamin B2 6) Botanpi extracted tannin weight % 3.0 5.0 70.899 0.5 0.07 0, O3 5 7) P OE hydrogenated castor oil derivative 0.5
8) Ethanol 20.09
) Ethinylestradiol 0.00110
) Fragrance appropriate amount 1,) 2
)3)4. ) are mixed and dissolved, and added to this 5)6)?
) 8) 9) The mixed solution of 10) was added with stirring to obtain a lotion as a homogeneous solution.
実施例4 乳液
1)セタノール
2)ステアリン酸
3)パルミチン酸
4)液状ラノリン
5)スクワラン
6)ミリスヂン酸イソプロピル
7)モノステアリン酸グリセリル
8)POE(20モル)
ソルビタンモノラウリン酸
エステル
9)アラントイン
10)プロピレングリコール
重量%
1.5
0.1
0.1
1.0
2.0
1.0
1.5
0.5
0.5
3.0
6
1])ポリエチレングリコール400 2.
012)l−リエタノールアミン 1.
013)カテキン 0.0
114)ガロイルグルコース混合物 0.09
15)精製水 84.81
)〜9)の各成分を混合して混合物を得た。別に、10
)〜14)の成分を混合して混合物を得た。それぞれの
混合物を別々に70℃に加熱溶解後、乳化機により混合
乳化したのち、熱交換冷却して乳液を得た。Example 4 Emulsion 1) Setanol 2) Stearic acid 3) Palmitic acid 4) Liquid lanolin 5) Squalane 6) Isopropyl myridate 7) Glyceryl monostearate 8) POE (20 mol) Sorbitan monolaurate 9) Allantoin 10) Propylene Glycol weight % 1.5 0.1 0.1 1.0 2.0 1.0 1.5 0.5 0.5 3.0 6 1]) Polyethylene glycol 400 2.
012) l-liethanolamine 1.
013) Catechin 0.0
114) Galloylglucose mixture 0.09
15) Purified water 84.81
) to 9) were mixed to obtain a mixture. Separately, 10
) to 14) were mixed to obtain a mixture. Each mixture was heated and dissolved separately at 70°C, mixed and emulsified using an emulsifier, and then cooled by heat exchange to obtain an emulsion.
実施例5 クリーム
1)グリセリン
2)ポリエチレングリコール
(分子量400)
3)グリヂルリヂン酸モノアンモニウム塩4)アラント
イン
5)シャクヤク抽出タンニン混合物
6)セタノール
7)スクワラン
重量%
5.0
2.0
0.1
0.1
5.0
4.0
5.0
7
8)ステアリン酸 1.09
)ミツロウ 1.010
)ワセlノン 1.01
]、) P OE (25モル)セヂルアルコール
2.0エーテル
12)グリルセリルモノステアレート 1.51
3)防腐剤 0.1514
)香料 0.1515)
精製水 67.0製法
5)〜14)を混合溶解し、同じく混合溶解した1)2
)3)4N、5)の中へ撹拌混合して乳化する。ホモジ
ナイザーにより乳化粒子を整え、その後、熱交換器にて
室温まで冷却してW10型クリームを得た。Example 5 Cream 1) Glycerin 2) Polyethylene glycol (molecular weight 400) 3) Glydyllidic acid monoammonium salt 4) Allantoin 5) Peony extract tannin mixture 6) Cetanol 7) Squalane weight % 5.0 2.0 0.1 0. 1 5.0 4.0 5.0 7 8) Stearic acid 1.09
) Beeswax 1.010
) Vaseline non 1.01
],) P OE (25 mol) Cedyl alcohol
2.0 Ether 12) Grillceryl Monostearate 1.51
3) Preservative 0.1514
)Fragrance 0.1515)
Purified water 67.0 Manufacturing method 5) to 14) were mixed and dissolved, and 1) and 2 were similarly mixed and dissolved.
) Stir and mix into 3) 4N and 5) to emulsify. The emulsified particles were prepared using a homogenizer, and then cooled to room temperature using a heat exchanger to obtain W10 type cream.
実施例6 パック
1)ポリビニルアルコール
2)ポリエチレングリコール
(分子量400)
3)グリセリン
4)エタノール(95%)
重量%
10.0
0.4
3.0
8.0
]
5)ゲラニン 0.16
)ペンタガロイルグルコース 0.27)防
腐剤 0.18)香料
0.19)精製水
78.1製法
室温で4)〜8)を混合溶解し、1)2)3)および9
)を80℃で混合溶解した中に撹拌添加した後、室温ま
で放冷してパックを得た。Example 6 Pack 1) Polyvinyl alcohol 2) Polyethylene glycol (molecular weight 400) 3) Glycerin 4) Ethanol (95%) Weight% 10.0 0.4 3.0 8.0] 5) Geranin 0.16
) Pentagalloylglucose 0.27) Preservatives 0.18) Flavorings
0.19) Purified water
78.1 Manufacturing method Mix and dissolve 4) to 8) at room temperature, 1) 2) 3) and 9
) was mixed and dissolved at 80° C. and then added with stirring, and then allowed to cool to room temperature to obtain a pack.
実施例? 軟膏 重量%1)固体
パラフィン 10.02)ピース
ワックス 10.03)スクワラ
ン 10.04)−\キザ
ガロイルグルコース 1.05)レゾルシン
0.16)亜鉛華
0.57)香料
適量8)ワセリン
68.4上記成分を混合し、混合物を8
0℃に加熱溶解した後、攪拌冷却を行い、軟膏を得た。Example? Ointment Weight% 1) Solid paraffin 10.02) Peace wax 10.03) Squalane 10.04) -\Quizagaloylglucose 1.05) Resorcinol 0.16) Zinc white
0.57) Fragrance
Appropriate amount 8) Vaseline
68.4 Mix the above ingredients and make the mixture 8
After heating and dissolving at 0° C., the mixture was stirred and cooled to obtain an ointment.
実施例8 ヘアトニック 重量%1)エタ
ノール 52.02)ヒノキ
ヂオール 0.53)ビタミン
EO13
4)POE(60モル)1.0
硬化ひまし油
5香料 適量6エピガ
ロカテキン 0.27精製水
45.08グリセリン
1.09色素
適量1)2) 3) 4)5)を室温
下、溶解してアルコール相を得た。6)7)8)9)の
混合液を加熱下に溶解し冷却し水相を得た。水相に前記
アルコール相を加え可溶化してヘアトニックを得た。Example 8 Hair tonic Weight% 1) Ethanol 52.02) Hinokidiol 0.53) Vitamin EO13 4) POE (60 mol) 1.0 Hydrogenated castor oil 5 Fragrance Appropriate amount 6 Epigallocatechin 0.27 Purified water
45.08 Glycerin
1.09 dye
Appropriate amounts of 1) 2) 3) 4) and 5) were dissolved at room temperature to obtain an alcohol phase. The mixed solution of 6), 7), 8), and 9) was dissolved under heating and cooled to obtain an aqueous phase. The alcohol phase was added to the aqueous phase and solubilized to obtain a hair tonic.
実施例9 ローション 重量%1)テト
ラガロイルグルコース 1.00
2) P OE (60モル)硬化しマシ油
2.03)グリセリン 10.
04)ジプロピレングリコール 10.05
)1.3−ブチレングリコール 5.06)ポ
リエチレングリコール1500 5.07)セヂ
ルイソオクタネート 10.08)スクワラ
ン 5.09)メチルパラベ
ン 1.010)カルボキシビニ
ルポリマー 0.311)へキザメタリン酸ソ
ーダ 0.0812)イオン交換水
11.013)水酸化カリウム
0.1214)イオン交換水
39.51)2)3)4.)5)6)を60℃
で加熱溶解する。これに7)8)9)を同じ<60℃に
加熱溶解したものを添加混合し、ホモミキサーで処理を
してゲルを作る。次にこのゲルに10)11)を、12
)に溶解せしめたものを徐添加しホモミキサーで分散し
た後、13)を14)に溶解したものを添加混合し、ホ
モミキサーで乳化1
2Example 9 Lotion Weight% 1) Tetragalloylglucose 1.00 2) P OE (60 mol) Hardened Mustard Oil
2.03) Glycerin 10.
04) Dipropylene glycol 10.05
) 1.3-Butylene glycol 5.06) Polyethylene glycol 1500 5.07) Cedyl isooctanate 10.08) Squalane 5.09) Methylparaben 1.010) Carboxyvinyl polymer 0.311) Sodium hexametaphosphate 0. 0812) Ion exchange water
11.013) Potassium hydroxide
0.1214) Ion exchange water
39.51)2)3)4. )5)6) at 60℃
Heat and dissolve. Add and mix 7), 8), and 9) heated and dissolved at <60°C, and process with a homomixer to form a gel. Next, add 10), 11) and 12 to this gel.
) was gradually added and dispersed with a homomixer, then the solution of 13) and 14) was added and mixed, and emulsified with a homomixer.
Claims (2)
特徴とする皮膚外用剤。(1) A skin external preparation characterized by containing a tannin compound as an active ingredient.
タンニンである請求項1記載の皮膚外用剤。 テトラ−GG ペンタ−GG ヘキサ−GG− ウンデ
カ−GG式1 式2 式3 ▲数式、化学式、表等があります▼▲数式、化学式、表
等があります▼▲数式、化学式、表等があります▼ n+k+l+m=1〜6 G:ガロイル基▲数式、化学式、表等があります▼ G−Gk−、G−Gl、G−Gm−、−G−Gn−、:
ポリガロイル基 GG:ガロタンニン(2) The skin external preparation according to claim 1, wherein the tannin compound is a gallotannin represented by the following formulas 1 to 3. Tetra-GG Penta-GG Hexa-GG- Undeca-GG Formula 1 Formula 2 Formula 3 ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼▲ There are mathematical formulas, chemical formulas, tables, etc. ▼▲ There are mathematical formulas, chemical formulas, tables, etc. ▼ n + k + l + m = 1 to 6 G: galloyl group ▲ Numerical formulas, chemical formulas, tables, etc. are available ▼ G-Gk-, G-Gl, G-Gm-, -G-Gn-,:
Polygalloyl group GG: gallotannin
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP31675389A JP2878353B2 (en) | 1989-12-06 | 1989-12-06 | External preparation for skin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP31675389A JP2878353B2 (en) | 1989-12-06 | 1989-12-06 | External preparation for skin |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH03178916A true JPH03178916A (en) | 1991-08-02 |
JP2878353B2 JP2878353B2 (en) | 1999-04-05 |
Family
ID=18080537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP31675389A Expired - Lifetime JP2878353B2 (en) | 1989-12-06 | 1989-12-06 | External preparation for skin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2878353B2 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19980034292A (en) * | 1996-11-06 | 1998-08-05 | 성재갑 | Skin whitening composition containing galloylquinic acid |
KR19980034291A (en) * | 1996-11-06 | 1998-08-05 | 성재갑 | Skin whitening composition containing galloylgalactose |
FR2787709A1 (en) * | 1998-12-23 | 2000-06-30 | Boots Co Plc | NOVEL DERMATOLOGICAL COMPOSITION BASED ON TANNIC ACID AND A MICROBIAL PROLIFERATION INHIBITOR |
WO2002002073A3 (en) * | 2000-06-30 | 2002-02-25 | Unilever Plc | Skin care anti-sebum compositions containing 3,4,4-trichlorocarbanilide |
KR100439590B1 (en) * | 2001-04-06 | 2004-07-12 | (주)큐티라이프 | Advanced Cosmetics Comprising Tannin as an Active Ingradient |
WO2005023207A1 (en) * | 2003-09-10 | 2005-03-17 | Unilever Plc | Method of decreasing sebum production |
JP2008214272A (en) * | 2007-03-05 | 2008-09-18 | Oriza Yuka Kk | Skin-lightening agent |
US20090170788A1 (en) * | 2006-01-16 | 2009-07-02 | Dong-Heon Shin | Novel use of 1, 2, 3, 4, 6-penta-o-galloyl-beta-d-glucose |
JP2011006341A (en) * | 2009-06-24 | 2011-01-13 | Hiroshima Univ | Skin external preparation for atopic dermatitis |
JP2013249263A (en) * | 2012-05-30 | 2013-12-12 | Ajinomoto Co Inc | Gallotannin-containing composition |
JP2016150916A (en) * | 2015-02-17 | 2016-08-22 | 株式会社マンダム | Sebum secretion inhibitor |
JP2016222736A (en) * | 2016-10-05 | 2016-12-28 | 味の素株式会社 | Gallotannin-containing composition |
-
1989
- 1989-12-06 JP JP31675389A patent/JP2878353B2/en not_active Expired - Lifetime
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19980034292A (en) * | 1996-11-06 | 1998-08-05 | 성재갑 | Skin whitening composition containing galloylquinic acid |
KR19980034291A (en) * | 1996-11-06 | 1998-08-05 | 성재갑 | Skin whitening composition containing galloylgalactose |
FR2787709A1 (en) * | 1998-12-23 | 2000-06-30 | Boots Co Plc | NOVEL DERMATOLOGICAL COMPOSITION BASED ON TANNIC ACID AND A MICROBIAL PROLIFERATION INHIBITOR |
WO2000038646A1 (en) * | 1998-12-23 | 2000-07-06 | The Boots Company Plc | Dermatological compositions containing tannic acid and a microbial proliferation inhibitor |
WO2002002073A3 (en) * | 2000-06-30 | 2002-02-25 | Unilever Plc | Skin care anti-sebum compositions containing 3,4,4-trichlorocarbanilide |
KR100439590B1 (en) * | 2001-04-06 | 2004-07-12 | (주)큐티라이프 | Advanced Cosmetics Comprising Tannin as an Active Ingradient |
WO2005023207A1 (en) * | 2003-09-10 | 2005-03-17 | Unilever Plc | Method of decreasing sebum production |
US20090170788A1 (en) * | 2006-01-16 | 2009-07-02 | Dong-Heon Shin | Novel use of 1, 2, 3, 4, 6-penta-o-galloyl-beta-d-glucose |
JP2008214272A (en) * | 2007-03-05 | 2008-09-18 | Oriza Yuka Kk | Skin-lightening agent |
JP2011006341A (en) * | 2009-06-24 | 2011-01-13 | Hiroshima Univ | Skin external preparation for atopic dermatitis |
JP2013249263A (en) * | 2012-05-30 | 2013-12-12 | Ajinomoto Co Inc | Gallotannin-containing composition |
JP2016150916A (en) * | 2015-02-17 | 2016-08-22 | 株式会社マンダム | Sebum secretion inhibitor |
JP2016222736A (en) * | 2016-10-05 | 2016-12-28 | 味の素株式会社 | Gallotannin-containing composition |
Also Published As
Publication number | Publication date |
---|---|
JP2878353B2 (en) | 1999-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100615116B1 (en) | Multivesicular emulsion topical delivery systems | |
US8679552B2 (en) | Acne vulgaris treatment regimen | |
JPS59108716A (en) | Antiacne composition | |
JPH03220129A (en) | Sebum suppressant | |
JPH03178916A (en) | Skin external agent | |
JP2764510B2 (en) | Whitening cosmetics | |
JPH11269034A (en) | Skin prepafation for external use for improving acne | |
JPS6360910A (en) | Skin drug for external use | |
JPS63179812A (en) | External preparation for skin | |
JPS63188628A (en) | Drug for skin external use | |
JPH07206658A (en) | Therapeutic agent for acne vulgaris | |
JP2696523B2 (en) | Anti-dandruff agent and hair cosmetic | |
JP2700070B2 (en) | Antimicrobial agent for Gram-positive anaerobic bacteria, external preparation for skin and oral composition using the same | |
CN110944649B (en) | Use of rhamnose and its derivatives as antifungal agents | |
JPS6322510A (en) | External preparation for skin | |
JP2001270828A (en) | External preparation for prevention and therapy of vulgaris acne and cosmetic prepared by formulating the same | |
JPH04305519A (en) | Skin humectant for external use | |
JPH02231408A (en) | Novel skin drug for external use | |
JPH11302147A (en) | Cosmetic | |
JPH10265365A (en) | External preparation for skin for pimple | |
JPS6360909A (en) | Skin drug for external use | |
JPS6360935A (en) | Sebum suppressive agent | |
JP6025676B2 (en) | Weakly acidic aqueous external composition containing Photosensitive Element 201 | |
JPS6322506A (en) | External preparation for skin | |
JP2001131025A (en) | Cosmetic for scalp and hair |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080122 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090122 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090122 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100122 Year of fee payment: 11 |
|
EXPY | Cancellation because of completion of term |